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teratomas after transplantation. As expected these cellsThe breakthrough invention of induced pluripotent stem
cells (iPSCs) ignited huge excitement with the promise of
unlimited autologous cell sources for future regenerative
medicine.1,2 However, before this expectation turns into
reality the safety and efficacy of these autologous cell
products have to be meticulously evaluated and validated.
Towards this end much research effort has been concen-
trated on three clinically relevant aspects: tumorigenesis,
immunogenesis, and efficacy. So far almost all of the in vivo
studies are carried out through syngeneicmouse or human to
immunocompromised mouse transplantations. While these
small animal models are important in the initial proof-of-
concept stages, the phylogenetic difference prevents a
reliable extrapolation of the findings to the human species.
On the other hand the ethical consideration renders it
impossible to test iPSC products directly in human body,
especially in early pre-clinical stage. The only ideal alter-
native model comes down to nonhuman primate due to its
closeness to the human in terms of phylogenetics, physi-
ology, and immune functions. One recent report published in
the journal of Cell Reports described in detail the autolo-
gous transplantation studies using rhesus monkey iPSCs andity of Chongqing Medical
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findings from this study are: 1) undifferentiated rhesus iPSCs
formed teratomas in the recipient animals as predicted, but
with a higher input cell threshold when compared to the test
using immunocompromised mouse. The formed teratomas
elicited immune response, characterized as infiltrations by
lymphocytes. 2) In contrast the differentiated iPSC product
differentiated further and formed nascent bone tissue in the
implants. The differentiated engraftments and thus-derived
bone tissues showed minimal signs of lymphocyte in-
filtrations. The significance of these findings is, for the first
time, iPSCs as well as their differentiated derivatives are put
to test in an autologous and immunocompetent nonhuman
primate model closely related to human biology. Thus
generated information will be extremely valuable in opti-
mizing human iPSC culture and differentiation protocols to
bring safe and effective cell products to the clinic trial.
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